Published in
Public Library of Science, PLoS ONE, 3(11), p. e0151703, 2016
DOI: 10.1371/journal.pone.0151703
Links
- ORCID
- ORCID
- ORCID
- ORCID
- Public Library of Science
- [hdl.handle.net]
- [hdl.handle.net]
- [hdl.handle.net]
- [hdl.handle.net] | PDF
- [hdl.handle.net]
- [hdl.handle.net]
- [journals.plos.org] | PDF
- [dea.lib.unideb.hu] | PDF
- [www.plosone.org] | PDF
- [dial.uclouvain.be] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort
,
Pierre Laukens,
Veronique Lefebvre
and other authors.
Full text: Download
Abstract
BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA